Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status.

Olivier MirCharles HonoréAli N ChamseddineJulien DômontSarah N DumontAndrea CavalcantiMatthieu FaronFrançoise RimareixLeila Haddag-MilianiCécile Le PéchouxAntonin LevyCharles CourtSylvain BriandElie FadelOlaf MercierArnaud BayleAnaïs BrunetCarine NgoEtienne RouleauJulien AdamAxel Le Cesne

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Oral vinorelbine is an effective, affordable, and well-tolerated regimen in patients with advanced, progressive DF. Prolonged activity was observed in patients with tumors harboring CTNNB1 p.S45F or p.S45P mutations.

Keyphrases

multiple sclerosis
phase ii study
squamous cell carcinoma
clinical trial
radiation therapy
rectal cancer